Abstract: A novel hair-setting composition having sufficient hair-setting ability, and a means to obtain such a hair-setting composition. An agent is provided for enhancing a hair-setting ability comprising an isomaltooligosaccharide as an active ingredient, and a hair-setting composition comprising the agent.

Abstract: The present invention provides topical compositions comprising a combination of an N-acyl dipeptide derivative and glycolic acid. The compositions provide enhanced penetration of the N-acyl dipeptide derivative into the skin.

Abstract: Disclosed is an efficacious, low-pH skin care composition that provides good sensory properties and has a low skin irritation potential. The low-pH composition includes an effective amount of a vitamin B3 compound and, optionally, one or more additional skin care actives to provide a skin health and/or appearance benefit. The low-pH composition also includes a pH buffer comprising lactic acid and sodium lactate, a polymer thickener comprising polyacrylate crosspolymer-6, and a silicone fluid having a kinematic viscosity of 100 cSt or less at 25° C. The pH of the low-pH composition can range from 2.0 to 5.0.

Abstract: The present invention relates to a tissue filler which comprises two different phases, namely cross-linked and non-cross-linked; wherein tricarboxylic acid is included within non-cross-linked phase; which is made of hyaluronic acid gel and a production method of this filler.

Abstract: The invention relates to cosmetic compositions comprising certain polyethers, polyether derivatives (e.g., polymeric alcohols and derivatives thereof), and methods of making and using the same, specifically in the field of cosmetic or personal care compositions applied to the skin or the hair.

Abstract: The present invention provides topical skin and hair care formulas comprised of natural ingredients such as butters and oils that softens, moisturizes and hydrates skin and hair including facial hair like beards. Furthermore, the invention includes palmitic, linoleic, stearic and oleic fatty acids, ingredients that balance oils on the skin. The invention promotes circulation and healthy skin cell growth with antioxidants vitamins like vitamins A, E and F. Triglycerides help nourish and condition the skin. In addition, cetyl esters not only condition the skin, but help lock in moisture.

Abstract: cosmetic water-in-oil emulsion (W/O emulsion) containing triglycerides, the preparation being free from mineral oil, paraffin wax, microcrystalline wax, shellac wax and polyethylene waxes, polyacrylates, crosslinked acrylate/C10-C30 alkylacrylate polymers, vinylpyrrolidone/hexadecene copolymers, 3-(4-methylbenzylidene)-campher, 2-hydroxy-4-methoxybenzophenone (INCI: oxybenzone), 2-ethylhexyl 4-methoxycinnamate (INCI: octylmethoxycinnamate), ethylhexyl-2-cyano-3,3-diphenylacrylate (INCI: octocrylene), parabens (in particular methyl-, propyl- and butylparaben), methylisothiazolinone, chloromethylisothiazolinone and DMDM-hydantoin, polyethylene glycol ethers or polyethylene glycol esters.

Abstract: A composition containing mixture organic oils topically applied to prevent dry hair and hair loss as a pomade. Hair that is commonly lost through heat, chemicals, and styles, can benefit from all-natural hair and scalp moisturizer. Hair that has been subject to weave glues and extremely tight braids can also benefit from the lack of chemicals in product ingredients. The composition is safe to the human body, with no side effects thereto, with the composition of grapeseed oil, rosemary, vitamin E, cold pressed castor oil, shea butter, candelilla vegan wax, and lavender oil.

Abstract: Provided herein are methods for treating chronic pain by administering low doses of buprenorphine twice daily (or once daily) via a transmucosal drug delivery device. The methods and devices efficiently treat chronic pain without significant side effects.

Abstract: The present disclosure provides a sprayable composition comprising about 1% w/v to about 20% w/v of oxybutynin, a penetration enhancer, at least 65% w/v of an aliphatic solvent, and a film forming excipient, wherein the film forming excipient has a solubility in water, at a pH between 1 and 10 and wherein the composition is a sprayable liquid solution that forms a protective and washable film when sprayed on skin The disclosure also provides a method of treating vasomotor symptoms, hot flashes, hyperhidrosis, osmiodrosis, incontinence, bladder spasms, pain following bladder surgery, or combinations thereof in a subject in need thereof, the method comprising topically administering to the subject the topical compositions as described herein.

Abstract: The present invention is directed to methods of treating psychiatric diseases and disorders comprising administering to a subject in need thereof at a frequency of no more than once every 28 days an injectable formulation comprising risperidone, triblock and diblock copolymers wherein the concentration of the risperidone is 250-400 mg/mL and injection volume is 1 mL or less.

Abstract: The present disclosure provides a cell housing device and a method of manufacturing such a device that has an array of channels to increase the ratio of surface area to volume.

Abstract: Described herein are intracameral implants including at least one therapeutic agent for treatment of at least one ocular condition. The implants described herein are not anchored to the ocular tissue, but rather are held in place by currents and gravity present in the anterior chamber of an eye. The implants are preferably polymeric, biodegradable and provide sustained release of at least one therapeutic agent to both the trabecular meshwork and associated ocular tissue and the fluids within the anterior chamber of an eye.

Abstract: An edible gummy which may be formed of edible material mixed in a solid solution with medicinal or nutritional supplements. The gummy features a body formed with a plurality of recesses therein extending between a central opening and a sidewall defining a perimeter of the body. The body is easily separated into substantially equal portions having a substantially equal volume of the edible material therein to make dosing of any supplement or medicine contained in the edible material both easy and accurate.

Abstract: The present invention relates to a mucoadhesive layer, preferably mucoadhesive buccal layer, comprising a non-nanoparticulate macrolide. Furthermore, the present invention relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer comprising a non-nanoparticulate macrolide, and further comprising a backing layer. The present invention also relates to a mucoadhesive film, preferably mucoadhesive buccal film, comprising a mucoadhesive layer, a backing layer, and an intermediate layer. The present invention further relates to a mucoadhesive layer or mucoadhesive film for use as a medicament and for use in preventing and/or treating transplant rejection. Moreover, the present invention relates to a method of preparing a mucoadhesive film.

Abstract: Provided herein are dry powder formulations comprising epinephrine alone or in combination with at least one enabling agent suitable for nasal application. Also provided are unit dose forms and devices comprising such formulations and methods of using such formulations for the treatment of various conditions including anaphylaxis, anaphylactoid reaction, respiratory conditions, hemodynamic collapse, and for administration during cardiopulmonary arrest and other life-threatening conditions.

Abstract: The present invention discloses a topical cream composition of eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with lavender oil as penetration enhancer and other excipients, which is effective to reduce the rate of skin hair growth and studies pertaining to pharmacodynamic behaviour thereof on hair growth rate. The invention further discloses a process for preparing a topical composition in the form of oil-in-water emulsion based cream composition which comprises eflornithine or its pharmaceutically acceptable salts or prodrugs thereof with a penetration enhancer and other excipients.

Abstract: The present disclosure provides compositions comprising a thermosensitive hydrogel formulation of anesthetic drugs and a triblock copolymer component, and methods of use and manufacture of the compositions for management of acute pain or pain associated with surgical procedure.

Abstract: The technical field of active substance preparations is belonged to, and provided are astaxanthin pickering emulsion with colon targeted delivery function, and a preparation method and application method thereof. The preparation method includes the following steps: S1, reparation of deacetylated-oxidized chitin nanofiber (DE-TO-ChNF)/carboxymethyl konjac glucomannan (CMKGM) nanogel; S2, preparation of astaxanthin oil phase; and S3, preparation astaxanthin pickering emulsion. Natural polysaccharide derivatives DE-TO-ChNF and CMKGM are used as raw materials, and stable crosslinking between covalent bonds and non-covalent bonds are formed between molecules in a composite system through the NHS/EDC, so as to form a stable nanogel. Then the nanogel is used as emulsifier and flaxseed oil rich in astaxanthin is used as oil phase to prepare the astaxanthin pickering emulsion by homogenization.

Abstract: Disclosed herein are novel pharmaceutical formulations of a neurokinin-1 (NK-1) receptor antagonist suitable for parenteral administration including intravenous administration. Also included are formulations including both the NK-1 receptor antagonist and dexamethasone sodium phosphate. The pharmaceutical formulations are stable oil-in-water emulsions for non-oral treatment of emesis and are particularly useful for treatment of subjects undergoing highly emetogenic cancer chemotherapy.

Abstract: Provided are novel lipid nanoparticles for delivering nucleic acids such as mRNA. Also provided are methods of making and using lipid nanoparticles for delivering nucleic acids such as mRNA.

Abstract: This application discloses a dispersible extended release granule composition comprising: (i) one or more active bio-active ingredients; (ii) at least one water-soluble gel forming polymer; and (iii) at least one water-insoluble lipid material, wherein the bio-active ingredient and the water-soluble gel forming polymer are present in the form of dry, pre-granulated particles either partially or fully coated with the water insoluble lipid material. Also disclosed is a process for preparing such extended release compositions and applications thereof.

Abstract: The present invention provides parenteral pharmaceutical compositions including therapeutically effective amounts of semaglutide or pharmaceutically acceptable salts thereof, the parenteral pharmaceutical compositions are formulated in depot form and provide low-burst release and a continued release profile. The present invention further provides methods of use of the parenteral pharmaceutical compositions for treating type-2 diabetes mellitus, obesity, and Parkinson's disease.

Abstract: A lyophilized stabilized formulation containing a live attenuated vaccine strain against tularemia.

Abstract: Herein described is a syringe assembly configured for the in situ lyophilization of an initial liquid preparation into a lyophilized product as well as the subsequent sealing of the lyophilized product for storage and transport, user reconstitution of the lyophilized product, and dispensing of the lyophilized product in rehydrated form to a patient in a medical setting, all in the same syringe. The combination lyophilization and dispensing syringe assemblies of the present invention greatly enhance the efficiency of the lyophilization process and find particular utility in conjunction with the dedicated lyophilization apparatus and methods described in U.S. Pat. Nos. 11,536,512 and 11,723,870. In particularly preferred embodiments, the present invention provides for shortened lyophilization cycles in a syringe barrel optionally fitted with a sealing Luer lock cap at its distal end and a vented stopper at its proximal end. During lyophilization, gas may flow out of the syringe barrel and through the stopper.

Abstract: The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a SGLT-2 inhibitor drug and a partner drug, processes for the preparation thereof, and their use to treat certain diseases.

Abstract: The present invention utilizes 3D printing technology, specifically fused filament fabrication (FFF) 3D printing, to produce solid dosage forms, such as pharmaceutical tablets. The production process utilizes novel printing filaments, typically on a spool, which contain the active ingredient. Such active-containing filaments have proved to be extremely robust and the principles outlined in the present disclosure provide access to a variety of viable formulations directly from a 3D printer. This, for the first time, affords a viable means for the in situ (e.g. within a pharmacy) 3D printing of personalized medicines tailored to a patient's needs. The invention also relates to purpose-built software for operating the printing apparatus, as well as local, national and global systems for monitoring the real time operation of a plurality of printing apparati to enable facile detection of malfunctions, thereby making regulatory approval viable and facilitating regulatory compliance.

Abstract: A composition, comprising: a plurality of mechanically-activated microcapsules; a mechanically-activated microcapsule defining a shell and an exterior surface; and the mechanically-activated microcapsule comprising one or more adhesion groups disposed Non the exterior surface of the mechanically-activated microcapsule, the one or more adhesion groups being configured to effect a covalent interaction, a non-covalent interaction, or both between the one or more adhesion groups and a matrix material, the covalent interaction, the non-covalent interaction, or both adhering the mechanically-activated microcapsule to the matrix material. Also provided are related methods and related articles.

Abstract: The present disclosure is related to a liquid viscoelastic swallowing aid formulated to promote safe swallowing of Solid Oral Dosage Forms (SODF), e.g., tablets and/or capsules, in a patient in need thereof, and uses of such a liquid viscoelastic swallowing aid.

Abstract: A process for manufacturing and using pancreatin micropellet cores and pancreatin micropellets which are substantially free of synthetic oils. In one embodiment, a pharmaceutical composition is provided comprising a pancreatin micropellet with the enteric coating being designed to deliver pancreatin to the upper portion of the intestine of a mammal for release.

Abstract: A heat and acid resistant probiotics microsphere having a size from 20 to 250 ?m that can readily be incorporated into food or beverages that subsequently undergo thermal treatment. The synbiotic core includes a seed layer formed from at least one polysaccharide. A probiotic microorganism is coated on the seed layer. An acid-resistant shell layer is positioned over the synbiotic core, the acid-resistant shell layer comprising one or more pH-responsive polymers. A heat-resistant bilayer shell is positioned over the acid-resistant shell layer, the heat-resistant bilayer shell including an inner shell layer and an outer shell layer, wherein the inner shell layer includes a heat-resistant liposome layer and the outer layer includes a heat-resistant disaccharide or polysaccharide.

Abstract: A method for making active pharmaceutical ingredient (“API”)-encapsulated polymer microspheres is provided, comprising: (A) preparing a dispersed phase (“DP”), comprising the steps of: (1) dissolving an API in a first solvent in a first vessel to form an API solution; (2) dissolving a biodegradable polymer in a second solvent in a second vessel to form a polymer solution; (3) combining the API solution and the polymer solution; and (4) mixing the combined solution to form the DP; (B) introducing the DP into a homogenization unit, wherein the time between the combining and the introducing consists of a predetermined contact time that is sufficiently short that the polymer does not undergo significant degradation attributable to the API, and the API does not undergo significant degradation or morphologic changes attributable to the polymer; (C) contacting the DP with a continuous phase (“CP”) in the homogenization unit; and (D) homogenizing the combined DP and CP.

Abstract: The invention provides a compound of compound of formula (I): or a salt thereof, wherein R1, n, L, and X have any of the values described herein, as well as compositions and lipid nanoparticles comprising a compound of formula I, and their use for delivering therapeutic agents such as siRNA and mRNA.

Abstract: Provided are a lipid and a composition that can effectively deliver an introduction compound such as a nucleic acid to a target cell, tissue, or the like in vivo.

Abstract: Provided are compositions that include compositions of galactosyl-conjugated lipid nanoparticles (LNPs) encapsulating one or more active agents. In some embodiments, the galactosyl-conjugated LNPs have a lipid component having D-Lin-MC3-DMA, ALC-0315 and SM-102, cholesterol. DSPC and DOPE, and DMG-2000-PEG. In some embodiments, the GalNAc-conjugated LNP has one or more galactosyl moieties bioconjugated to cholesterol present with a lipid component of the GalNAc-conjugated LNP. Also provided are methods for treating and/or preventing diseases, disorders, and/or conditions associated with undesirable PCSK9 gene expression, optionally a cardiovascular disease, disorder, or condition, including but not limited to atherosclerosis and/or thrombosis, and sepsis, septic shock, cytokine storm, or sequelae thereof.

Abstract: The present disclosure provides compositions which shown preferential targeting or delivery of a nucleic acid composition to a particular organ. In some embodiments, the composition comprises a steroid or sterol, an ionizable cationic lipid, a phospholipid, a PEG lipid, and a permanently cationic lipid which may be used to deliver a nucleic acid.

Abstract: Embodiments of the invention are directed to compositions containing cannabinoid, cannabidiol, cannabidiol isomer, or cannabidiol analog and combinations thereof for treating viral infections, and methods for treating viral infections by topically or orally administering compositions containing cannabinoid, cannabidiol, or cannabidiol analog to the patient in need of treatment.

Abstract: Transdermal delivery devices for the delivery of cannabidiol (CBD) are shown and described. In reservoir patch designs, a microporous, hydrophilic membrane and a backing define a reservoir that houses a mixture of CBD, a polar liquid, and a gelling agent. The hydrophilic membrane is coated with an amine-compatible silicone skin adhesive. In a monolithic design, a release liner is coated with a mixture of CBD and a PIB or amine-compatible silicone skin adhesive laminated to the backing material. In either design, the CBD may be provided as a pure compound or as a component of a cannabis oil.

Abstract: A pharmaceutical composition, and methods for using a pharmaceutical composition, for treating osteoarthritis in a subject in need thereof, the pharmaceutical composition including cannabidiol or a pharmaceutically acceptable salt thereof; and especially wherein administration of the cannabidiol is by a transdermal pharmaceutical gel composition. A method is disclosed for treating one or more symptoms of osteoarthritis in a patient. The method includes transdermally administering an effective amount of cannabidiol (CBD) to the patient wherein one or more symptoms of osteoarthritis are treated in the patient.

Abstract: The present invention relates to an antimicrobial adjuvant containing a biphenyl derivative compound as an active ingredient, and a technology of various uses thereof. The compound of the present invention reduces the dosage of polymyxin antibiotics, which are administered to inhibit the proliferation of gram-negative bacteria, by enhancing the sensitivity of the gram-negative bacteria with respect to the polymyxin antibiotics, is concomitantly administered with the polymyxin antibiotics to show gram-negative bacteria growth inhibitory and killing effects, may notably reduce side effects such as nephrotoxicity, and may prevent or treat sepsis and septic shock due to antibiotic overuse.

Abstract: Described in certain example embodiments herein are compositions and methods that can, in some embodiments, improve avian health, particularly poultry health. In some embodiments, the method can include administering, to an avian, optionally a poultry animal, an effective amount of a stilbene composition including one or more stilbenes. In some embodiments the stilbene composition including one or more stilbenes includes resveratrol, pterostilbene, piceatannol, or any combination thereof.

Abstract: The present invention relates to an oral thin film comprising at least one matrix polymer and at least one active pharmaceutical ingredient, wherein the at least one active pharmaceutical ingredient is an acid or a base, characterised in that the at least one active pharmaceutical ingredient is present in the form of a mixture which comprises the at least one active pharmaceutical ingredient both in the form of the free acid or base and in the form of a pharmaceutically acceptable salt, a method for producing said oral thin film, and the use of such an oral thin film as a medicament.

Abstract: Pharmaceutical compositions of epinephrine and its prodrugs are described, the prodrugs having a half-life of less than one minute, and the compositions having enhanced active component permeation properties are described.

Abstract: A method for the prevention or reduction of sensitization to a pharmaceutical drug for Parkinson's disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof. A method for the optimization of the dosage of a pharmaceutical drug for Parkinson's disease, the method comprising administering to a subject in need thereof a therapeutically effective amount of a compound of Formula I or a pharmaceutically acceptable salt thereof.

Abstract: The present disclosure provides novel topical compositions comprising endoxifen and salts and solvates thereof and methods for making the compositions. Certain compounds have been combined to make a stable topical compositions comprising endoxifen. The present disclosure also provides methods for treatment of hormone-dependent breast and hormone-dependent reproductive tract disorders.

Abstract: The present invention provides a novel combination therapy with PD-1 blockade therapy. A pharmaceutical composition which comprises a substance capable of enhancing T cell receptor (TCR) signaling and is administered before, after or simultaneously with the administration of a PD-1 signaling inhibitor. A drug which enhances PD-1 signaling inhibitory activity, comprising a CD45 inhibitor and/or a cell. A TCR signaling enhancer comprising a CD45 inhibitor and/or a cell.

Abstract: This disclosure describes a safe, effective, and novel method of preventing or treating atrial fibrillation, atrial flutter, atrial tachycardia, premature ventricular contractions, ventricular tachycardia, or a combination thereof using an initial intravenous sotalol dose followed by same day discharge and, in some cases, discharge following the administration of an intravenous dose of sotalol. This shortened time frame allows subjects to be discharged from the hospital less than 18 hours after sotalol initiation.

Abstract: The present invention concerns the use of aprotic polar solvents, water, and an ionization stabilizing agent to prepare stable therapeutic formulations, particularly sustained release formulations, of a variety of active pharmaceutical ingredients (APIs), such as, e.g., levothyroxine. In particular, the invention concerns the use of aprotic polar solvents and at least one ionization stabilizing agent to prepare stable therapeutic formulations of a variety of APIs by dissolving at least one API in an aprotic polar solvent system to produce a stable sustained release therapeutic formulation useful in treating, preventing and/or diagnosing diseases or physical disorders in humans and veterinary animals. The invention also provides methods of manufacturing such formulations.

Abstract: Disclosed herein are compounds, compositions, and methods for inhibiting DGAT1 and DGAT2. Also disclosed are kits comprising DGAT1 and DGAT2 inhibitors. The compounds, compositions, and methods can be used to treat a subject with cancer, such as liver cancer.

Abstract: The present invention concerns the use of aprotic polar solvents and an ionization stabilizing agent to prepare stable therapeutic formulations of levothyroxine by dissolving levothyroxine in an aprotic polar solvent system that can then be used to treat, prevent, and/or diagnose certain diseases and disorders in humans and veterinary animals by administration of the formulation thereto. In certain embodiments, the invention is directed to formulations comprising levothyroxine, and optionally one or more additional therapeutic agents, dissolved in an aprotic polar solvent system, such as a DMSO/water admixture comprising at least one ionization stabilizing excipient in a concentration sufficient to impart physical and chemical stability to the therapeutic agent. The invention also provides methods of use of such formulations in treating, preventing, and/or diagnosing diseases and disorders, and methods of manufacturing such formulations.